奥氮平联合氟西汀治疗对抑郁症患者血清NE水平以及抑郁情绪影响的临床研究

摘要 目的：研究奥氮平联合氟西汀治疗抑郁症患者的临床疗效，并探讨联合治疗对抑郁症患者血清去甲肾上腺素（Norepinephrine，NE）和抑郁情绪的影响。方法：纳入2018年6月到2020年5月在我院接受治疗的抑郁症患者56例，随机数表法将其分为对照组和研究组两组。对照组患者接受氟西汀治疗，而研究组患者接受奥氮平联合氟西汀治疗，两组患者均治疗8周。比较两组患者年龄、性别、身高、BMI以及病程等一般资料，并比较两组患者临床治疗疗效、治疗期间不良反应发生率、治疗前后血清NE水平。用汉密顿抑郁量表(Hamilton Rating Scale for Depression，HAMD)和抑郁自评量表（Self-Rating Depression Scale，SDS）评估两组患者抑郁情绪。结果：两组患者性别、年龄、身高、BMI、病程以及合并症等一般情况均显示无显著差异（P>0.05）。研究组治疗总有效率（92.86%）显著高于对照组（64.29%）总治疗有效率（P<0.05），但研究组患者治疗期间不良发生率（32.14%）与对照组（28.57%）比较无显著差异（P>0.05）。治疗后，两组患者血清NE水平均较治疗前显著升高（P<0.05），并且研究组患者治疗后血清NE水平均显著高于对照组患者（P<0.05）；两组患者血清HAMD和SDS评分均较治疗前显著降低（P<0.05），并且研究组患者治疗后HAMD和SDS评分均显著低于对照组患者（P<0.05）。结论：奥氮平联合氟西汀治疗抑郁症患者安全有效，不良反应发生率较低，可有效升高抑郁症患者血清NE水平，而改善患者抑郁情绪。

Clinical Study of the Effect of Olanzapine Combined with Fluoxetine Treatment on Serum NE Level and Depression in Patients with Depression

ABSTRACT Objective: To study the clinical efficacy of olanzapine combined with fluoxetine in the treatment of patients with depression, and to explore the effect of combined therapy on serum norepinephrine (NE) and depression in patients with depression. Methods: Fifty-six cases of depression patients who were treated in our hospital from June 2018 to May 2020 were included, and they were divided into two groups: control group and study group by random number table method. Patients in the control group received fluoxetine treatment, while patients in the study group received olanzapine combined with fluoxetine treatment. Patients in both groups were treated for 8 weeks. The two groups of patients were compared with general data such as age, gender, height, BMI, and disease course, and the clinical treatment efficacy, incidence of adverse reactions during treatment, and serum NE levels before and after treatment were compared between the two groups. The Hamilton Rating Scale for Depression (HAMD) and Self-Rating Depression Scale (SDS) were used to evaluate depression in the two groups. Results: There were no significant differences in gender, age, height, BMI, course of disease, and comorbidities between the two groups (P>0.05). The total effective rate of treatment in the study group (92.86%) was significantly higher than the total effective rate in the control group (64.29%) (P<0.05), but the incidence of adverse events in the study group during treatment (32.14%) was compared with that in the control group (28.57%) There was no significant difference (P>0.05). After treatment, the serum NE levels of the two groups of patients were significantly higher than those before treatment (P<0.05), and the serum NE levels of the patients in the study group were significantly higher than those in the control group (P<0.05); the serum HAMD and HAMD levels of the two groups were significantly higher after treatment. The SDS scores were significantly lower than those before treatment (P<0.05), and the HAMD and SDS scores of patients in the study group were significantly lower than those in the control group after treatment (P<0.05). Conclusion: Olanzapine combined with fluoxetine is safe and effective in the treatment of patients with depression, and the incidence of adverse reactions is low. It can effectively increase the serum NE level of patients with depression and improve the depression of patients.